Washington, DC: Politics and Prose Publishing
Explosive market growth for weight-loss medications The GLP-1 market is booming: $26 billion in sales in 2024, projected to hit $100470 billion annually by 2032, dominated by just two pharmaceutical giants: Novo Nordisk and Eli Lilly
The multidistrict litigation (MDL) against pharmaceutical companies Novo Nordisk and Eli Lilly, involving GLP-1 drugs like Ozempic, Wegovy, Trulicity, and Mounjaro, continues to develop as plaintiffs allege these medications have caused significant gastrointestinal injuries
Relationship to Afamelanotide and Bremelanotide For example, Afamelanotide, sometimes called Melanotan I, is a distinct linear analog with greater emphasis on MC1R-related pigmentation and photoprotection
Using HSA and FSA Accounts to Pay for Semaglutide PlexusDx compounded semaglutide injections are eligible for payment through Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA), allowing patients to use pre-tax dollars for weight loss therapy
Vitamin E Protects against free radicals and nourishes for smooth, healthy skin